Symptomatic response to testosterone treatment in dieting obese men with low testosterone levels in a randomized, placebo-controlled clinical trial

M Ng Tang Fui; R Hoermann; LA Prendergast; JD Zajac; M Grossmann

Journal article

Symptomatic response to testosterone treatment in dieting obese men with low testosterone levels in a randomized, placebo-controlled clinical trial

M Ng Tang Fui, R Hoermann, LA Prendergast, JD Zajac, M Grossmann

International Journal of Obesity | SPRINGERNATURE | Published : 2017

DOI: 10.1038/ijo.2016.242

Abstract

Background:Obese men commonly have reductions in circulating testosterone and report symptoms consistent with androgen deficiency. We hypothesized that testosterone treatment improves constitutional and sexual symptoms over and above the effects of weight loss alone.Methods:We conducted a pre-specified analysis of a randomized double-blind, placebo-controlled trial at a tertiary referral center. About 100 obese men (body mass index (BMI)≥30 kg m - 2) with a repeated total testosterone level ≤12 nmol l -1 and a median age of 53 years (interquartile range 47-60) receiving 10 weeks of a very-low-energy diet (VLED) followed by 46 weeks of weight maintenance were randomly assigned at baseline to ..

View full abstract

University of Melbourne Researchers

Mark Ng Tang Fui Author

Jeffrey Zajac Author

Mathis Grossmann Author

Related Projects (2)

A CLINICAL TRIAL TO ASSESS THE EFFECT OF TESTOSTERONE TREATMENT COMBINED WITH DIETARY RESTRICTION ON BODY FAT MASS AND MUSCLE FUNCTION IN OBESE MEN

Obesity, an increasing health and economic burden, is associated with lowered testosterone levels in men. While both dietary restriction and..

CONTROL OF MUSCULOSKELETAL FUNCTION AND INSULIN RESISTANCE BY ANDROGENS IN MALES

Male sex hormone or androgen deficiency (AD) is a common, but under-diagnosed condition. AD decreases general well being and contributes to ..

Grants

Awarded by National Health and Medical Research Council (Australia)

Funding Acknowledgements

MNTF was supported by a postgraduate scholarship (1055305) and MG by a Career Development Fellowship (1024139) both from the National Health and Medical Research Council (Australia). We are most grateful to Professor David Handelsman and Ms Reena Desai (ANZAC Research Institute, University of Sydney, Australia) for performing the LCMS/MS assay measurements and to Mrs Jenny Healy for assistance with the data collection. Drs Grossmann and Ng Tang Fui had full access to all the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis. Bayer Pharma AG (Berlin, Germany) provided testosterone, placebo and financial support to conduct investigations, but had no role in trial design, data analysis or writing the manuscript.